234 related articles for article (PubMed ID: 21163673)
1. Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer.
Saad F; Eastham JA; Smith MR
Urol Oncol; 2012; 30(4):369-78. PubMed ID: 21163673
[TBL] [Abstract][Full Text] [Related]
2. Bone-marker levels in patients with prostate cancer: potential correlations with outcomes.
Saad F; Lipton A
Curr Opin Support Palliat Care; 2010 Sep; 4(3):127-34. PubMed ID: 20489645
[TBL] [Abstract][Full Text] [Related]
3. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials.
Som A; Tu SM; Liu J; Wang X; Qiao W; Logothetis C; Corn PG
Br J Cancer; 2012 Oct; 107(9):1547-53. PubMed ID: 23033003
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.
Michaelson MD; Kaufman DS; Kantoff P; Oh WK; Smith MR
Cancer; 2006 Aug; 107(3):530-5. PubMed ID: 16804927
[TBL] [Abstract][Full Text] [Related]
5. Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates?
Lipton A; Costa L; Coleman RE
Breast Dis; 2011; 33(2):59-69. PubMed ID: 22142664
[TBL] [Abstract][Full Text] [Related]
6. Consensus on the utility of bone markers in the malignant bone disease setting.
Coleman R; Costa L; Saad F; Cook R; Hadji P; Terpos E; Garnero P; Brown J; Body JJ; Smith M; Lee KA; Major P; Dimopoulos M; Lipton A
Crit Rev Oncol Hematol; 2011 Dec; 80(3):411-32. PubMed ID: 21411334
[TBL] [Abstract][Full Text] [Related]
7. Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event.
Hahn NM; Yiannoutsos CT; Kirkpatrick K; Sharma J; Sweeney CJ
Clin Genitourin Cancer; 2014 Feb; 12(1):33-40.e4. PubMed ID: 24126237
[TBL] [Abstract][Full Text] [Related]
8. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
9. Markers of bone turnover in prostate cancer.
Garnero P
Cancer Treat Rev; 2001 Jun; 27(3):187-92; discussion 193-6. PubMed ID: 11417970
[TBL] [Abstract][Full Text] [Related]
10. Preservation of bone health in prostate cancer.
Lattouf JB; Saad F
Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
[TBL] [Abstract][Full Text] [Related]
11. Clinical usefulness of bone markers in prostate cancer with bone metastasis.
Kamiya N; Suzuki H; Endo T; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Nov; 19(11):968-79. PubMed ID: 22805007
[TBL] [Abstract][Full Text] [Related]
12. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
13. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
Saad F; McKiernan J; Eastham J
Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
[TBL] [Abstract][Full Text] [Related]
14. Markers of bone metabolism in prostate cancer.
Smith MR
Cancer Treat Rev; 2006; 32 Suppl 1():23-6. PubMed ID: 16680835
[TBL] [Abstract][Full Text] [Related]
15. Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases.
López-Carrizosa MC; Samper-Ots PM; Pérez AR
Clin Transl Oncol; 2010 Aug; 12(8):568-73. PubMed ID: 20709654
[TBL] [Abstract][Full Text] [Related]
16. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy.
Tamada T; Sone T; Tomomitsu T; Jo Y; Tanaka H; Fukunaga M
J Bone Miner Metab; 2001; 19(1):45-51. PubMed ID: 11156473
[TBL] [Abstract][Full Text] [Related]
17. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
[TBL] [Abstract][Full Text] [Related]
18. Maintaining bone health in prostate cancer throughout the disease continuum.
Saad F; Eastham J
Semin Oncol; 2010 Jun; 37 Suppl 1():S30-7. PubMed ID: 20682370
[TBL] [Abstract][Full Text] [Related]
19. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.
Smith MR; Cook RJ; Coleman R; Brown J; Lipton A; Major P; Hei YJ; Saad F
Urology; 2007 Aug; 70(2):315-9. PubMed ID: 17826496
[TBL] [Abstract][Full Text] [Related]
20. Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid.
Lein M; Miller K; Wirth M; Weissbach L; May C; Schmidt K; Haus U; Schrader M; Jung K
Prostate; 2009 May; 69(6):624-32. PubMed ID: 19143027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]